Posted by Michael Wonder on 24 Apr 2023
Changes to treatment phases and authority levels in medicines for the treatment of Alzheimer’s disease
24 April 2023 - From 1 May 2023, the PBS item codes for donepezil, galantamine, memantine and rivastigmine, for the treatment of mild to moderately severe Alzheimer’s disease, will be updated to combine the ‘Initial 1’ and ‘Initial 2’ treatment phases.
The changes will be made based on the post-market review of PBS Authority required (Written) listings.
